Clinical trial · Interventional
Dietary Intervention With High Phenolic EVOO in CLL
Effect of Dietary Intervention With High-Oleocanthal and Oleacin Extra Virgin Olive Oil in Patients With Chronic Lymphocytic Leukemia a Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Daily intake of extra virgin olive oil (EVOO), which is the major component of the Mediterranean diet and also a source of monounsaturated fat, may be partly responsible for the increased life expectancy of the Mediterranean people. A high dietary intake of EVOO is correlated with lower incidence of cancer, cardiovascular disease, metabolic diseases, Alzheimer's disease and osteoporosis Oleocanthal, a phenolic derivative of extra virgin olive oil, has important health promoting anti-cancerous properties, since it can inhibit the growth and promote the apoptosis of several cancer cells. The purpose of the present study was to investigate the effect of dietary intake of olive oil rich in oleocanthal on hematological, metabolical, cell progression markers and disease progression in patients with Chronic Lymphocytic Leukemia. The aim is also to study the possible association of apoptosis in the mechanism of action of virgin olive oil phenols in a patient with CLL in order to find the possible mechanism of the cellular action of oleocanthal in neoplasia. After the screening of \>300 EVOO samples the investigators selected an EVOO with high oleocanthal and oleacin concentration of 416 and 284 mg/Kg respectively (EVOO OC/OL). Pilot dietary intervention was made in a group of 21 patients with chronic lymphocytic leukemia (CLL) who did not follow any treatment. EVOO was administered 40 ml/day for six months. Biochemical, hematological and molecular markers were studied six month before the intervention and six month during the intervention
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| High phenolic EVOO intake | Dietary Supplement | — | UNRESOLVED |
| No High phenolic EVOO intake | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- High phenolic EVOO intake
- description
- Patients with CLL consumed before their meals, 40 ml/day of EVOO rich in oleocanthal and oleacin for 6 months,
- interventionNames
- Dietary Supplement: High phenolic EVOO intake
- type
- EXPERIMENTAL
- label
- No High phenolic EVOO intake
- description
- Patient's history were recorded for third and sixth month before dietary the intervention, taking into consideration that the patients did'nt consume high phenolic EVOO.
- interventionNames
- Dietary Supplement: No High phenolic EVOO intake
Primary outcomes (2)
- measure
- Effect of the dietary intake of high phenolic EVOO on hematologic profile
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 54 Years
- Maximum age
- 84 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed Chronic lymphocytic leukemia (CLL) * Untreated CLL patients having Rai stage 0 to II * Must be able to consume high phenolic EVOO according to the instructions Exclusion Criteria: * Neoplasic comorbidities and received any chemotherapy, * Severe metabolic disease such us insulin dependent diabetes or severe kidney disease
References
Publications (16)
- BACKGROUNDParkinson L, Keast R. Oleocanthal, a phenolic derived from virgin olive oil: a review of the beneficial effects on inflammatory disease. Int J Mol Sci. 2014 Jul 11;15(7):12323-34. doi: 10.3390/ijms150712323. PMID 25019344
- BACKGROUNDBeauchamp GK, Keast RS, Morel D, Lin J, Pika J, Han Q, Lee CH, Smith AB, Breslin PA. Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. Nature. 2005 Sep 1;437(7055):45-6. doi: 10.1038/437045a. PMID 16136122
- BACKGROUNDPang KL, Chin KY. The Biological Activities of Oleocanthal from a Molecular Perspective. Nutrients. 2018 May 6;10(5):570. doi: 10.3390/nu10050570. PMID 29734791
- BACKGROUNDSabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010 Jun;102(3):83-7. No abstract available. PMID 21171509
- BACKGROUNDHallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015 May;90(5):446-60. doi: 10.1002/ajh.23979. PMID 25908509
- BACKGROUNDRai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-234. Blood. 2016 Oct 27;128(17):2109. doi: 10.1182/blood-2016-08-737650. No abstract available. PMID 27789434
- BACKGROUNDDomen J, Cheshier SH, Weissman IL. The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential. J Exp Med. 2000 Jan 17;191(2):253-64. doi: 10.1084/jem.191.2.253. PMID 10637270
- BACKGROUNDMarschitz I, Tinhofer I, Hittmair A, Egle A, Kos M, Greil R. Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques. Am J Clin Pathol. 2000 Feb;113(2):219-29. doi: 10.1309/491W-L1TN-UFQX-T61B.